This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations 8 Q&As
1 Citations 7 Q&As
Facts about Oxidized low-density lipoprotein receptor 1.
Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro- atherogenic cellular responses including a decrease of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it serves as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation.
Human | |
---|---|
Gene Name: | OLR1 |
Uniprot: | P78380 |
Entrez: | 4973 |
Belongs to: |
---|
No superfamily |
CLEC8A; CLEC8ASLOX1; C-type lectin domain family 8 member A; hLOX-1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; Lectin-type oxidized LDL receptor 1; LOX1; LOX-1; LOX1ox LDL receptor 1; LOXIN; OLR1; oxidised low density lipoprotein (lectin-like) receptor 1; oxidized low density lipoprotein (lectin-like) receptor 1; oxidized low-density lipoprotein receptor 1; oxidized low-density lipoprotein receptor 1, soluble form; Ox-LDL receptor 1; SCARE1; scavenger receptor class E, member 1; SR-E1
Mass (kDA):
30.959 kDA
Human | |
---|---|
Location: | 12p13.2 |
Sequence: | 12; NC_000012.12 (10158300..10172191, complement) |
Expressed at high level in endothelial cells and vascular-rich organs such as placenta, lung, liver and brain, aortic intima, bone marrow, spinal cord and substantia nigra. Also expressed at the surface of dendritic cells. Widely expressed at intermediate and low level.
Cell membrane; Lipid-anchor. Cell membrane; Single-pass type II membrane protein. Membrane raft. Secreted. A secreted form also exists. Localization to membrane rafts requires palmitoylation.
Boster bio anti-OLR1 antibodies can be used for studies on humans and mice. It reacts with OLR1 proteins in the human and mouse tissues. If you are looking to detect the OLR1 protein in humans, you can use Boster bio anti-OLR1 antibody catalog number A00760-4. The following features are contained in the Boster bio anti-OLR1 antibody:
Boster Bio's Anti-OLR1 marker has been shown to bind to Human OLR1 (and LOX-1) members of the C-type lectin family. It is found on the membrane of all choroidal neovascular cells, and has been characterized by FISH as a scavenger for macrophages. In addition to LOX1 it is also expressed on other membranes of choroidal neovascularization.
The overexpression of OLR1 is associated with the growth of pancreatic cancerous cells in mice models. OLR1 knockdown inhibited the growth of orthotopic-xenograft models as well in the development of Bxpc-3 pancreatic tumor cells. These studies utilized the lentivirus system OLR1 overexpression to induce OLR1 knockdown. Moreover, knockdown of OLR1 decreased the weight of orthotopic xenograft models.
OLR1 is an overexpression which promotes cell proliferation and invasion in the aorta. OLR1 knockdown inhibits these processes. OLR1 increase in expression has a positive effect on wound healing activity, while OLR1 knockdown decreased migration compared to control cells. Western Analyses of blots proved the presence of OLR1 protein levels. These results support the notion of OLR1 playing a major part in the pathogenesis and progression of the influenza.
OLR1 downregulation decreases ICH-induced neuronal loss in brain tissues. In addition, knockdown of OLR1 reverses the post-ICH activation of p38 and protects post-ICH brain tissue from damage to the brain that is secondary. Inhibiting OLR1 knockdown also decreases the amount of brain water and the size of hematoma. While OLR1 knockdown reduces neuron loss caused by ICH it remains to be determined how to activate OLR1 in live.
The Mouse Lox-1 ELISA kit uses plasma (EDTA), or serum (EDTA) for samples. The test sample is then added to 96-well strips plates containing a similar amount of mouse standards. The OLR1 antibody is then added to the mouse samples. The ELISA test then gives the resulting oxidized LDL in the samples.
These studies have demonstrated that OLR1 expression is linked with body weight in KO mice following virus infection. OLR1 also plays a part in the replication and spread of the PR8 virus to the lung. To identify this protein in KO mice, the intranasally-inoculated PR8 virus was used. The body weight of both mice was then measured. The symbol with an open sign indicates PBS controls.
400 ng of total mouse RNA was reverse transcribed into complementary (cDNA) DNA using the Transcriptor High Fidelity synthesizer kit of Roche Diagnostics. The cDNA samples were then amplified using TaqMan probes and hydrolysis probes. The pre-incubation procedure was performed at 95 degrees Celsius to conduct the PCR reactions. This was performed for 10 minutes.
The OLR1 gene is located on the chromosome 12p13.1-p12.3. It spans seven kb and has six exons. One SNP in this gene results in an amino-acid substitution in position 167. It has been linked to hypertension, cardiovascular disease and MI. The occurrence of the gene in diseases is believed to be a result of genetics. There are two variants of the OLR1 gene: dominant and recessive. This is due to alternative splicing.
Metastasis is enhanced by the overexpression of OLR1 cells. Overexpression of this receptor increases the migration of breast cancer cells via the NF-kB. OLR1 is also expressed in vascular smooth muscle cells and platelets. OLR1 activation is associated to a higher risk of developing cardiovascular disease. Its role in pancreatic carcinoma remains an unanswered question.
After cleaning PBMCs and extracting RNA, 400 ng of total RNA was reverse-transcribed and converted to complementary (c)DNA. To determine OLR1 expression within human cells the cDNA samples were subjected to QRTPCR. The qRTPCR process included a pre-incubation step at 85°C using hydrolysis probes and TaqMan.
OLR1 expression correlates with T-cell-inflamed signatures of the tumor microenvironment. Merck18 has identified this signature as the average of CD8A and CD8B expression. The results of this study suggest that OLR1 could be a great biomarker for immunotherapy. However, further research is necessary to confirm these findings. A positive correlation with OLR1 in humans is still the only way to confirm its potential use in immunotherapy for NSCLC.
OLR1 is increased in pancreatic cancer. Researchers employed a lentivirus to increase OLR1 expression in pancreatic carcinoma. These results are in line with the results of cellular immunofluorescence research, which demonstrated that OLR1 is expressed primarily in the cell membrane and cytoplasm. IHC scores for pancreatic cancer tissue were higher than those for normal pancreatic tissue.
OLR1 and the mRNA levels of IL17A in FP artery diseases were significantly higher than those in healthy controls. Although statistically not significant, male patients had higher levels of IL17A than female patients. IL17A in patients with FP artery disease was higher than in healthy patients. These results suggest that OLR1 is correlated with IL17A.
PMID: 9052782 by Sawamura T., et al. An endothelial receptor for oxidized low-density lipoprotein.
PMID: 9763655 by Li X., et al. Assignment of the human oxidized low-density lipoprotein receptor gene (OLR1) to chromosome 12p13.1-->p12.3, and identification of a polymorphic CA-repeat marker in the OLR1 gene.
*More publications can be found for each product on its corresponding product page